Study of lymphangioleiomyomatosis (LAM) disease process
Part of Blood & lymphatic, Brain & nervous system, Cancer, Genetic & congenital, Immune system & allergy, Lungs & breathing clinical trials.
This study looks at the natural history and disease process of lymphangioleiomyomatosis (LAM), a rare lung disease that mostly affects women. It may help understand how LAM progresses and how it affects daily life, and may include exercise testing and other evaluations.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 16 years old or older.
- You must have a diagnosis of lymphangioleiomyomatosis (LAM) or have findings on lung biopsy or chest imaging (X-ray or CT) that are consistent with LAM.
- You must not have a serious lung or other illness that would make study participation risky.
- If you are a woman of childbearing age, you must not be pregnant or nursing during the study, and some tests (like lung biopsy, certain imaging, and exercise tests) will be postponed until after pregnancy or nursing.
- If you are a control participant (without LAM), you must have no lung or other systemic disease, and if you are a smoker, you must have smoked for at least 1 year but still have normal lung function and chest imaging.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests whether breathing in albuterol can improve symptoms or lung function in people with lymphangioleiomyomatosis (LAM). It’s mainly about safety and early signs of benefit by targeting airflow problems.
This study is a registry that gathers information from pregnant women with Tuberous Sclerosis Complex (TSC) or Lymphangioleiomyomatosis (LAM), as well as infants born to them. The goal is to better understand how these conditions affect pregnancy and the baby's health.
This study sets up a database and collection of “biosamples” (like blood or other body samples) from people with tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis (LAM). The goal is to better understand how these conditions change over time and support future research.
This trial studies whether sirolimus can be used safely and works over time for LAM, a rare lung disease. You may be able to join if you already use (or cannot use) certain lung-targeting medicines called mTOR inhibitors, and if you can do regular clinic visits and breathing tests.
This study tests the long-term safety and tolerability of the drug imatinib in women with LAM, a rare lung disease that causes cysts. It may help stabilize lung function over time.
This trial is a national registry that collects information about people with lymphangioleiomyomatosis to better understand the condition and care over time. It may help by contributing real-world data from patients with sporadic disease or related tuberous sclerosis.
Hear when a new Pneumothorax trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.